Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 15 Endometrial Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Squamous Cell Carcinoma of Head and Neck 5 Neoplasm Metastasis 5 Breast Neoplasms 5 Uterine Cervical Neoplasms 4 Rectal Neoplasms 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Pancreatic Neoplasms 3 Melanoma 3 Colonic Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Osteosarcoma 2 Locally Advanced Rectal Cancer (LARC) 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Neuroendocrine 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 20 pomalidomide 18 Lenalidomide 17 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Cisplatin 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Carboplatin 7 zanubrutinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × dostarlimab × 1 year × Clear all

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡